REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced that it will report top-line Phase 2 clinical study results of FDX-104 in acneiform rash associated with targeted antibody treatments and head and neck cancers on Thursday, December 3, and host a conference call and webcast with slides at 8:30am eastern time.
|Conference Call Details|
|Thursday, December 3, 2015 @ 8:30am Eastern|
|Replays, available through December 17, 2015:|
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.
CONTACT: Dorit Hayon Foamix Pharmaceuticals Ltd. +972-8-9316233 BD@foamixpharma.com US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 email@example.com